Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03768570 | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | active not recruiting | Phase 2 | 82 | Canadian Cancer Trials GroupNETWORK | 3 | Jun 18, 2026 |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05204186 | Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence(COMORBID-AI) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00756639 | Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | active not recruiting | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03375307 | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07029256 | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639983 | Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma | not yet recruiting | Phase 2 | 44 | Sheng TaiOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT02717156 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | active not recruiting | Phase 2 | 70 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07524426 | Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment(LORUP) | recruiting | N/A | 248 | Umeå UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07260162 | Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)(PERSEVERANCE) | not yet recruiting | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06421142 | FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer | recruiting | N/A | 80 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06388720 | The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy(IMGeS) | recruiting | Phase 2 | 82 | National Cancer Center, KoreaOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | active not recruiting | Phase 2 | 375 | BicycleTx LimitedINDUSTRY | 21 | May 27, 2026 | clinicaltrials |
| NCT07608224 | HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC(HOPE-07-MIBC) | not yet recruiting | Phase 2 / Phase 3 | 240 | West China HospitalOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07475403 | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03291028 | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | active not recruiting | — | 15 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04216290 | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07581496 | T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer | recruiting | — | 35 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06586255 | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | recruiting | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07048496 | Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support(BCG at Home) | recruiting | N/A | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03933826 | CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer(CISTO) | active not recruiting | — | 570 | University of WashingtonOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03601455 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | active not recruiting | Phase 2 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06822010 | SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma | recruiting | Phase 2 | 28 | Rutgers, The State University of New JerseyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06892860 | Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer(DISCUS) | recruiting | Phase 2 | 320 | Queen Mary University of LondonOTHER | 3 | May 6, 2026 | clinicaltrials |
| NCT07231809 | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients(HIVEC) | not yet recruiting | N/A | 50 | AC.TA. S.r.l.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03757949 | Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | active not recruiting | Phase 3 | 203 | SWOG Cancer Research NetworkNETWORK | 1 | May 4, 2026 | clinicaltrials |
| NCT06986304 | Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy(SR-ULM BC) | recruiting | — | 30 | Duke UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT05646485 | Bladder Cancer Screening Trial | recruiting | N/A | 1,000 | University of Texas Southwestern Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07413523 | Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA(ASTRA) | recruiting | N/A | 44 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 | 32 | Emory UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555756 | An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models | not yet recruiting | N/A | 1,080 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 2 | Apr 29, 2026 | clinicaltrials |
| NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial(CALCIFER) | not yet recruiting | Phase 1 | 20 | Juan Luis VásquezOTHER | 0 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials